Stryker (NYSE:SYK)‘s stock had its “buy” rating restated by investment analysts at Royal Bank of Canada in a research note issued to investors on Tuesday. They presently have a $175.00 price objective on the medical technology company’s stock. Royal Bank of Canada’s price target indicates a potential upside of 8.84% from the company’s current price.

Several other analysts also recently commented on the company. Robert W. Baird raised Stryker from a “neutral” rating to an “outperform” rating and raised their price objective for the stock from $161.00 to $173.00 in a research note on Thursday, November 16th. Zacks Investment Research downgraded Stryker from a “hold” rating to a “sell” rating in a research note on Monday, October 16th. BMO Capital Markets raised Stryker to a “market perform” rating and set a $163.00 price objective on the stock in a research note on Tuesday, December 12th. Stifel Nicolaus raised their price objective on Stryker from $158.00 to $168.00 and gave the stock a “buy” rating in a research note on Friday, October 27th. Finally, SunTrust Banks reaffirmed a “buy” rating and set a $161.00 price objective on shares of Stryker in a research note on Friday, November 17th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and thirteen have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $156.60.

Stryker (SYK) traded down $2.54 during mid-day trading on Tuesday, hitting $160.78. The stock had a trading volume of 1,820,000 shares, compared to its average volume of 1,110,000. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.61 and a current ratio of 2.37. The firm has a market cap of $60,170.00, a P/E ratio of 34.28, a P/E/G ratio of 2.30 and a beta of 0.78. Stryker has a one year low of $117.64 and a one year high of $164.20.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, October 26th. The medical technology company reported $1.52 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.50 by $0.02. The business had revenue of $3.01 billion for the quarter, compared to the consensus estimate of $2.97 billion. Stryker had a return on equity of 24.11% and a net margin of 14.67%. The firm’s revenue was up 6.1% compared to the same quarter last year. During the same quarter last year, the business posted $1.39 EPS. analysts predict that Stryker will post 6.47 EPS for the current year.

In other Stryker news, insider Lonny J. Carpenter sold 5,000 shares of the stock in a transaction dated Friday, November 3rd. The stock was sold at an average price of $155.34, for a total transaction of $776,700.00. Following the completion of the transaction, the insider now owns 83,207 shares in the company, valued at approximately $12,925,375.38. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 7.40% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently added to or reduced their stakes in SYK. Blue Chip Partners Inc. grew its holdings in shares of Stryker by 0.3% in the 2nd quarter. Blue Chip Partners Inc. now owns 1,781 shares of the medical technology company’s stock valued at $247,000 after acquiring an additional 6 shares in the last quarter. WFG Advisors LP grew its holdings in shares of Stryker by 1.6% in the 2nd quarter. WFG Advisors LP now owns 2,041 shares of the medical technology company’s stock valued at $283,000 after acquiring an additional 32 shares in the last quarter. Armor Investment Advisors LLC grew its holdings in shares of Stryker by 1.0% in the 2nd quarter. Armor Investment Advisors LLC now owns 5,000 shares of the medical technology company’s stock valued at $694,000 after acquiring an additional 50 shares in the last quarter. Advisory Services Network LLC grew its holdings in shares of Stryker by 1.8% in the 2nd quarter. Advisory Services Network LLC now owns 3,398 shares of the medical technology company’s stock valued at $472,000 after acquiring an additional 59 shares in the last quarter. Finally, Essex Financial Services Inc. grew its holdings in shares of Stryker by 0.6% in the 2nd quarter. Essex Financial Services Inc. now owns 11,220 shares of the medical technology company’s stock valued at $1,557,000 after acquiring an additional 62 shares in the last quarter. Hedge funds and other institutional investors own 74.90% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at https://www.watchlistnews.com/stryker-syk-receives-buy-rating-from-royal-bank-of-canada/1800331.html.

Stryker Company Profile

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Analyst Recommendations for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.